You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 18, 2025

Drugs in MeSH Category Cytochrome P-450 CYP2C19 Inhibitors


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer DIFLUCAN IN SODIUM CHLORIDE 0.9% fluconazole INJECTABLE;INJECTION 019950-006 Jan 29, 1990 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Pfizer DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER fluconazole INJECTABLE;INJECTION 019950-004 Jan 29, 1990 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Gedeon Richter Usa FLUCONAZOLE fluconazole TABLET;ORAL 076432-003 Jul 29, 2004 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Apotex TICLOPIDINE HYDROCHLORIDE ticlopidine hydrochloride TABLET;ORAL 075089-001 Jul 1, 1999 RX No Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Norvium Bioscience FLUVOXAMINE MALEATE fluvoxamine maleate TABLET;ORAL 075889-003 Nov 29, 2000 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Dr Reddys Labs Inc FLUCONAZOLE fluconazole TABLET;ORAL 076658-004 Jul 29, 2004 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Cytochrome P-450 CYP2C19 Inhibitors Market Analysis and Financial Projection

The market dynamics and patent landscape for Cytochrome P-450 CYP2C19 inhibitors reflect a rapidly evolving field driven by personalized medicine, pharmacogenomics, and strategic intellectual property management. These inhibitors play critical roles in drug metabolism, impacting therapeutic outcomes across cardiovascular, gastrointestinal, and psychiatric treatments.


Market Dynamics

Global Market Growth

The CYP2C19 detection and inhibitor market is experiencing robust growth:

  • Detection kits reached $99.5 billion in 2024, projected to grow at a 12.4% CAGR in North America and 16.2% CAGR in Asia-Pacific through 2031[1].
  • Diagnostic tests are the fastest-growing segment, driven by demand for precision dosing and adverse reaction prevention[1].
  • Key drivers: Rising cardiovascular disease prevalence, increased adoption of pharmacogenomic testing, and healthcare investments in genomic research[1][14].

Regional Insights

  • North America: Dominates with >40% market share ($39.8 billion in 2024), fueled by advanced healthcare infrastructure[1].
  • Asia-Pacific: Fastest-growing region (23% market share) due to expanding genomic research and high rates of slow metabolizers (15–20% of the population)[1][10].
  • Europe: Holds >30% market share ($29.8 billion), with steady growth in genetic screening applications[1].

Key Therapeutic Areas

Application Market Impact Example Drugs
Cardiology High Clopidogrel, Prasugrel[6]
Gastroenterology Critical Omeprazole, Esomeprazole[10]
Psychiatry Moderate Fluoxetine, Fluvoxamine[4]

Genotyping-guided therapy for clopidogrel users could save $444,852 annually per 100 patients by reducing adverse cardiac events[6].


Patent Landscape

Strategic Patenting

  • Omeprazole/Esomeprazole: AstraZeneca’s chiral switch from racemic omeprazole to esomeprazole extended market exclusivity. Esomeprazole’s reduced CYP2C19 dependency minimized interpatient variability, securing $6.26 billion annual sales at peak[10][18].
  • Broad patent thickets: Omeprazole was shielded by 40+ patents in the U.S., delaying generics until 2006[18].

Innovative Formulations

  • Voriconazole combinations: Patent EP-1713477-B1 covers antifungal CYP2C19 inhibitor combinations, enhancing therapeutic efficacy[2].
  • Ritonavir: Used as a CYP3A4 inhibitor in HIV therapy, its synthesis and polymorph patents illustrate complex protection strategies[9].

Emerging Trends

  • AI-driven drug discovery: Machine learning models predict CYP2C19 inhibition with 80% accuracy, aiding safer drug design[5].
  • Natural inhibitors: Berry constituents (e.g., anthocyanidins) show moderate CYP2C19 inhibition, though 50–750× less potent than fluvoxamine[8].

Clinical and Economic Considerations

  • Drug interactions: Omeprazole’s irreversible CYP2C19 inhibition risks reducing clopidogrel’s antiplatelet effect[11].
  • Cost-effectiveness: Genotyping is economically viable in Asia (saving ~$5,000 per 100 tested) but less so in Caucasians[3][14].
  • Market shifts: CYP2C19 genotyping could reduce clopidogrel use by 20%, favoring prasugrel/ticagrelor in PCI patients[6].

Future Outlook

  1. Personalized medicine: Expansion of genetic testing kits ($228.9 billion Asia-Pacific market by 2031)[1].
  2. Patent expiries: New formulations and diagnostic-linked patents will dominate, as seen with voxilaprevir’s HCV protease inhibitor protections[13].
  3. Therapeutic diversification: CYPs are targets in oncology (e.g., breast/prostate cancer) and virology (HCV/HIV), with 17% of new drugs being chiral[12][10].

Highlight: "The justification for [esomeprazole’s] chiral switch was the improved bioavailability due to differences in pharmacokinetic profiles." [10]

This landscape underscores the interplay between innovative drug development, strategic IP management, and evolving clinical practices in optimizing CYP2C19 inhibitor therapies.

References

  1. https://www.cognitivemarketresearch.com/human-cyp2c19-gene-detection-kit-market-report
  2. https://pubchem.ncbi.nlm.nih.gov/patent/EP-1713477-B1
  3. https://pubmed.ncbi.nlm.nih.gov/12222994/
  4. https://examine.com/glossary/cyp2c19-inhibitors/
  5. https://pubmed.ncbi.nlm.nih.gov/35081108/
  6. https://pubmed.ncbi.nlm.nih.gov/26108379/
  7. https://www.epo.org/en/boards-of-appeal/decisions/t140285eu1
  8. https://pubmed.ncbi.nlm.nih.gov/19585468/
  9. https://www.wipo.int/edocs/pubdocs/en/patents/946/wipo_pub_946.pdf
  10. https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c02239
  11. https://pubmed.ncbi.nlm.nih.gov/21795468/
  12. https://pubmed.ncbi.nlm.nih.gov/24660660/
  13. https://unitaid.org/uploads/UTD17004_04_Voxilaprevir_v04.pdf
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC7719394/
  15. https://meshb.nlm.nih.gov/record/ui?ui=D065689
  16. https://pubmed.ncbi.nlm.nih.gov/22239545/
  17. https://www.databridgemarketresearch.com/reports/global-cytochrome-inhibitors-market
  18. https://gabi-journal.net/a-case-study-of-astrazenecas-omeprazole-esomeprazole-chiral-switch-strategy.html

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.